Preparing Performance Verification Dossiers for Overseas Registration of Laboratory Equipment: A Practical Guide

To prepare performance verification documentation for overseas registration of laboratory equipment, companies must first confirm whether the product is regulated as a medical device in the target country, determine the registration pathway and applicant based on product risk classification, assess the reusability of existing performance data generated under NMPA, CE, FDA, or ISO 13485 systems, and conduct a gap analysis against target-market standards, test methods, sample sizes, and environmental adaptability requirements. The documentation package should cover performance specification definitions, test methods, test reports, critical component parameters, software verification, packaging and transport validation, and stability data, while ensuring that risk management documents and performance evidence corroborate each other.

This article was prepared by the AIMEILI Regulatory Editorial Team, based on the AIMEILI registration practice question bank, medical device international registration knowledge base, and public regulatory information. Specific projects must always follow the latest requirements of the target country's regulatory authorities and the product's supporting documentation.

Applicable Scenarios and Core Questions

Laboratory equipment refers to instruments used in in vitro diagnostics, life science research, clinical testing, and laboratory automation. Common examples include analyzers, centrifuges, PCR thermal cyclers, chemistry analyzers, immunoassay systems, and laboratory information management systems. When companies plan to export such equipment, they must determine whether the target country regulates the product as a medical device. Different jurisdictions define laboratory equipment differently: some manage it as a medical device, while others treat it as general laboratory equipment. This directly determines whether registration is required and what performance verification data must be prepared.

The core issue is not simply compiling a test report. Companies must answer three questions: Does the target market require registration? Which risk class should the product be assigned to? What local standards and review requirements must the performance verification data satisfy? Only by answering these questions clearly can an effective documentation pathway be planned.

Laboratory equipment often integrates hardware, software, and consumables. Performance verification may involve whole-system performance, module performance, software functionality, and compatibility with matched reagents or consumables. If companies focus only on standalone instrument performance and ignore software and ancillary product evidence, they are likely to receive additional information requests during scientific evaluation.

This scenario applies to companies entering overseas markets for the first time, as well as to companies that already hold multiple registrations but need to add a new target country. First-time exporters must establish a technical file from scratch, while multi-country registrants should assess the reuse rate of existing data to reduce duplicate testing.

Registration Determination Logic

Companies should first confirm the intended use, mechanism of action, use environment, human contact type, duration of use, sterility, energy source, software content, and IVD attributes, and then determine the risk classification and application pathway. If the pathway is incorrectly determined, subsequent translation, notarization, authorization, testing, and supplementary data will all move in the wrong direction.

For target-market projects, the applicant and local responsibility boundaries must also be confirmed. Who holds the certificate? Who handles regulatory communication? Who manages import and post-market events? Who initiates changes? Who maintains renewal documentation? If these issues are only vaguely addressed in commercial contracts, market control may be affected later.

Documentation and Evidence

Typical documentation includes product description, model/specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system certification, technical files, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance data.

The quality of documentation lies not in quantity but in consistency. Label claims, test report model coverage, clinical evidence scope, risk management conclusions, label warnings, and registration application information must support each other. Regulatory authorities evaluate whether the product is safe, effective, and traceable for the intended use, not whether the company has uploaded many files.

Common Mistakes

The most common problem is treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documents without restructuring evidence according to the target market pathway.
• Including too many models or specifications, but test reports, clinical evidence, or labels do not cover all variants.
• Selecting a local agent only based on sales cooperation, without defining regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistencies among labels, instructions for use, promotional materials, and registration data, leading to deficiencies or post-market compliance risks.
• Failing to plan for multi-country data reuse, causing each country to repeat document assembly, increasing cost and timeline.

Pre-Project Checklist

Before project initiation, companies are advised to confirm the documentation baseline with an internal checklist, so that critical evidence gaps are detected before application.

• Organize the target product list, model/specification matrix, and intended use descriptions.
• Verify whether existing NMPA, CE, FDA, or other market registration dossiers can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documentation, clinical evaluations, and English instructions for use.
• Confirm the local agent or authorized representative’s responsibilities, fees, certificate control, and exit mechanism.
• Establish a target-country gap analysis table, identifying items that require supplemental testing, translation, notarization, or additional declarations.

AIMEILI Perspective

AIMEILI advises companies not to interpret target-market registration as a one-time document submission, but rather to manage it as an overseas market access engineering project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, and then converting it for each country, is usually faster and more stable than assembling documents country by country. This approach also benefits future changes and renewals.

From a project management perspective, companies should control three things in advance: product classification and pathway determination, consistency of the documentation evidence chain, and the regulatory responsibility boundaries of local partners. If any of these are unclear, even a voluminous documentation package may suffer repeated cycles of deficiencies, agent communication, and post-market maintenance issues.

Frequently Asked Follow-up Questions

Can domestic documentation be submitted directly for target-market registration?

Domestic data can serve as a base, but generally cannot be submitted as-is. Companies must adjust the documentation structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

As soon as the target market and product list are confirmed. The earlier the gap assessment is completed, the earlier supplementary testing, translation, label adjustments, and agent selection can be arranged.

Why does local agent selection affect registration quality?

The local agent is usually involved in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and long-term market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project register containing product lists, model specifications, registration pathways, document owners, translation status, testing status, local agent communication records, and planned submission dates in one table. This helps identify data gaps in a timely manner and enables management to assess whether the project will affect launch timelines.

For companies with existing multi-country registration experience, an evidence reuse matrix should be established to clarify which documents can be used as core evidence and which must be reissued or supplemented according to national requirements. In particular, labels and instructions for use, clinical evaluation, risk management, performance verification, and quality system certificates must maintain version consistency.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a regulatory review perspective, quality system documentation is not an isolated certificate. Regulatory authorities usually pay attention to consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the product under application, or if production address, model specifications, IFU version, and test reports are inconsistent, even a large amount of documentation may trigger additional clarification requests.

Companies should establish an evidence consistency checklist before submission, mapping product name, model/specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/IFU version, and quality system certificate. This foundational step can significantly reduce the likelihood of deficiencies, especially for projects submitted under multiple GHWP member states or multiple product series.

Localization Conversion and Agent Responsibilities

Target-market registration projects typically involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies must confirm in advance whether the local partner is responsible only for submitting documentation, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and long-term market stability.

Labels, instructions for use, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market dossiers, the focus of localization conversion is to convert reusable evidence into an application structure acceptable to the target country, rather than creating a new set of isolated documentation.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean the end of compliance work. Companies still need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label version control, and regulatory update records. Many companies invest significant effort during the registration phase but neglect post-market maintenance. Later, if production address changes, model expansions, IFU updates, or agent changes occur, certificate validity may become disconnected from market sales.

AIMEILI recommends incorporating this issue into annual international registration planning: first define target-market priorities, then establish a reusable documentation package and country-specific gap lists, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. This approach not only improves the efficiency of individual country registrations, but also helps companies build repeatable overseas compliance capabilities, reducing the cost of starting from zero for every new market.

Content Review and Application Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory documents; industry media and project experience are used as auxiliary references. Applicability: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements of the target country’s regulatory authorities, testing conclusions, or legal advice.

Published: 2026-08-26. Updated: 2026-08-26.